NIH-Funded Team-Based Care Model Achieves Significant Blood Pressure Reduction in Underserved Populations
核心洞察
A clinical trial at 36 federally qualified health centers demonstrated that team-based care reduced systolic blood pressure by more than 15 mm Hg compared to 9 mm Hg with standard care in over 1,270 low-income participants.
The intervention achieved optimal blood pressure control (less than 120 mm Hg) in 21.8% of patients versus 15.1% in the control group at 18 months, with potential for 10% reduction in cardiovascular events.
The scalable care model cost approximately $760 per patient, significantly less than treating subsequent heart conditions, demonstrating both clinical effectiveness and economic viability.
A National Institutes of Health-funded clinical trial has demonstrated that a comprehensive team-based care model can significantly reduce blood pressure in underserved populations, offering a scalable solution to address hypertension disparities in low-income communities. The study, conducted across 36 federally qualified health centers in Louisiana and Mississippi, enrolled more than 1,270 participants aged 40 or older and achieved substantial improvements in blood pressure control compared to standard care approaches.
Intervention Strategy and Study Design
The team-based intervention incorporated multiple coordinated components including intensive blood pressure management, systematic tracking with provider feedback, health coaching focused on lifestyle modifications and medication adherence, and home blood pressure monitoring. Participants qualified for enrollment if they had systolic blood pressure of at least 140 mm Hg without medication or at least 130 mm Hg with medication, representing patients with uncontrolled hypertension despite treatment.
The intervention group demonstrated superior outcomes compared to enhanced usual care, which included physician education on hypertension guidelines. The team-based approach reduced systolic blood pressure by more than 15 mm Hg versus approximately 9 mm Hg in the control group. According to prior research cited in the study, this difference could translate to a 10% reduction in cardiovascular events.
Clinical Outcomes and Cost-Effectiveness
At 18 months, optimal blood pressure control with systolic pressure less than 120 mm Hg was achieved in 21.8% of patients in the intervention group compared to 15.1% in the control group. Additionally, 47.7% of intervention patients achieved systolic blood pressure less than 130 mm Hg versus 36.4% in the control group.
The economic analysis revealed that the team-based intervention averaged approximately $760 per patient, representing a cost-effective approach that is significantly less expensive than treating resultant cardiovascular conditions. Most participants had long-standing, treated but uncontrolled hypertension, demonstrating that these blood pressure reductions are achievable in real-world clinical settings.
Addressing Health Disparities
The study addresses a critical gap in hypertension management for vulnerable populations. According to the Centers for Disease Control and Prevention data cited in the research, only 1 in 4 adults with high blood pressure has their condition under control, with 37 million U.S. adults having uncontrolled high blood pressure of 140/90 mmHg or higher. Lower-income Americans experience particularly high prevalence of hypertension combined with low control rates, contributing to increased disease burden.
"Evidence-based strategies to treat uncontrolled hypertension among low-income Americans are severely lacking, even though we know this condition is a huge risk factor for more serious heart complications," said NIH Director Jay Bhattacharya, M.D., Ph.D. "This study shows us that we can deploy an affordable, tested program to help reduce the burden of heart disease in this population."
Implementation and Scalability
The team-based model demonstrated practical advantages by reducing provider burden while supporting patient self-management through home monitoring and health coaching. The researchers concluded that these strategies can be scaled to other primary care settings and have the potential to improve hypertension control in similarly underserved populations.
Administrator Tom Engels of HRSA, which oversees the Health Center Program, emphasized the broader implications: "Health centers play a critical role in chronic disease prevention and management, including preventing and managing hypertension. Because uncontrolled hypertension is a leading cause of death in the United States, the public health implications of this trial are significant."
The clinical trial was led by researchers at University of Texas Southwestern Medical Center, Dallas, and Tulane University, New Orleans, with support from multiple NIH institutes including the National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute of General Medical Sciences, and National Institute on Minority Health and Health Disparities.